14 August 2025

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Launch of SlimBiome® in leading US brand

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes announces the launch of a product containing its award-winning appetite reducing SlimBiome® in Hydroxycut, which markets itself as the No. 1 selling weight loss supplement brand in the United States of America ("USA").

This announcement confirms the launch of the first product under the brand name 'Hydroxycut Hunger Control', and follows on from the first order announcement on 15 April 2025. The product is sold through online outlets and retail outlets such as Walmart (as shown here), and product marketing includes two studies carried out by OptiBiotix which demonstrate reduction in hunger of 74% and 83%.  Orders for a second product application have been received and expected to be launched later this year.

Hydroxycut is America's No.1 selling weight loss supplement brand and has sold over 100 million bottles of its product over the last two decades*. Hydroxycut products are sold online and via major retail outlets across the USA such as Walmart, Kroger, Target, GNC, Kmart, Albertsons, CVS Pharmacies and more. The brand has high customer awareness and in recent years has become increasingly known for its science backed products. The introduction of SlimBiome®, with its scientifically substantiated health claims of hunger control, helps to differentiate these products from other weight management products on the market.

This news is significant for the Company as it represents the inclusion of SlimBiome® in the products of one of the USA's most popular weight management brands which has led to orders totalling just under five metric tonnes for SlimBiome® in 2025. The Board believes that the opportunity has potential for future development and will provide further updates in due course.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the launch of products containing our patented award winning SlimBiome® in the USA. The Company has been working with Hydroxycut for almost two years to carry out human studies which allows the brand to make health claims of reductions in hunger of 74% and 83% in the USA. The launch with Hydroxycut substantiates the science behind SlimBiome and helps build the SlimBiome brand in consumer markets around the world. This is another example of the Company launching products with well-known brands in key international markets which if successful, individually and collectively, have the potential to make a significant contribution to future sales growth and shareholder value."

* Hydroxycut: America's Best Selling Weight Loss Supplement

The Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions.  These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.